Healthcare Zydus Cadila inks non-exclusive licensing pact with Gilead Sciences to manufacture and market Remdesivir Updated : June 13, 2020 08:59 AM IST As part of the non-exclusive agreement, Zydus will receive the manufacturing know-how from Gilead Sciences Inc. Zydus will leverage its ability to scale up production to reach patients across India and across the 127 countries in Gilead’s Global Patient Solution region. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.